Cite
HARVARD Citation
Fitz-Patrick, D. et al. (2019). Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials. Modern rheumatology. 29 (6), pp. 1042-1052. [Online].